Evaluable karyotypes were available in 776 of 1148 adult patients who were entered on acute myeloid leukemia (AML) treatment protocols of the Eastern Cooperative Oncology Group. Among these, we found seven patients (0.9%) with t(9;22)(q34;q11), the Philadelphia (Ph) chromosome, in bone marrow metaphases. All fulfilled the FAB criteria for AML (three M0, two M1, two M2), although one patient presented with an additional, distinct lymphoid blast cell population. Chromosomal aberrations in addition to the Ph chromosome were seen in four patients (including two cases of monosomy 7). Molecular analysis by polymerase chain reaction in four patients tested revealed variable BCR/ABL transcript forms (ela2, b2a2, b3a2, b2a3+e1a2). By immunophenotyping, all seven patients were myeloid based on the overall antigen expression pattern. However, all but one demonstrated lymphoid-associated antigens on the myeloid blast cells. The six evaluable patients failed to respond to treatment with a standard anthracycline/cytosine arabinoside-containing regimen. We conclude that the incidence of the Ph chromosome in AML is very low. Although both genotypically and phenotypically heterogenous, Ph chromosome-positive AML, represents a clinically distinct entity with poor outcome.
Introduction
Although the cytogenetic hallmark for chronic myeloid leukemia (CML), the Philadelphia (Ph) chromosome is also the single most common cytogenetic defect in adult patients with acute lymphocytic leukemia (ALL) and has been reported in a few patients with acute myeloid leukemia (AML). 1 This reciprocal translocation, t(9;22)(q34;q11), disrupts the normal ABL and BCR genes on the long arm of chromosome 9 and 22, respectively. Of the two chimeric genes formed as a result of this translocation, the BCR/ABL gene on the chromosome 22 derivative (Ph chromosome) appears to play the principal role in cell transformation. 1 In the majority of CML patients, the break occurs in the major breakpoint cluster region of the BCR gene. The BCR/ABL mRNA transcript processed from the resulting fusion gene contains BCR exon b2 or b3 fused to ABL exon a2 (b2a2, b3a2) and is translated into a fusion protein with an approximate molecular mass of 210 kDa. About two-thirds of ALL cases have breakpoints that result in the fusion of BCR exon e1 to ABL exon a2 (e1a2 junction). In this case, the resulting chimeric mRNA is translated into a smaller 190 kDa fusion protein. Presence of these transcript forms is, however, not disease-specific in that CML-typical transcript forms or the dual expression of p190 and p210 protein enco-ding fusion mRNAs can be seen in patients with ALL, [1] [2] [3] as well as AML. 1, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The reported incidence of the Ph chromosome in AML ranges from Ͻ1% to 4%, a range that may reflect the inclusion of myeloid blast crisis of CML in some instances. All cases in the literature were diagnosed based on FAB criteria. 15 Although immunophenotypic data are limited, expression of one or more lymphoid antigens by the myeloid blast cells 6, 7, 9, 12, 14, 16, 17 or the presence of a distinct lymphoid blast cell component in addition to the myeloblast population 9, 12 have been observed in the majority of cases. Occasional follow-up information from patients with Ph-positive AML in relapse demonstrated marked changes in the antigen profile. 12, 17, 18 These findings suggest that Ph-positive AML is a prototype of transformation of a multipotent stem cell. This concept is further supported by the fact that the most frequent cytogenetic abnormality seen in addition to the Ph chromosome is monosomy 7, 6, 7, 19 an aberration typically associated with multilineage leukemia or myelodysplasia. 20, 21 In an effort to establish the true incidence of Ph chromosome-positive AML patients and to characterize their biologic and clinical characteristics, the Eastern Cooperative Oncology Group (ECOG) performed a retrospective analysis in 776 patients entered on ECOG AML protocols between May 1986 and December 1997 in whom cytogenetic information was available.
Materials and methods

Patient population
Between May 1986 and December 1997, 1148 samples were referred to ECOG's immunophenotyping laboratory from patients entered on ECOG de novo AML protocols, E1490, E3993, PC486, E3489, E2491, E4995, and simultaneously registered to the laboratory protocol E1485. Ph chromosomepositive cases were found among patients treated on E3489 (12 mg/m 2 intravenous idarubicin daily × 3 days, and 25 mg/m 2 intravenous cytarabine push on day 1, followed by 100 mg/m 2 continuously infused for 7 days) or on E3993 (45 mg/m 2 intravenous daunorubicin daily × 3 days, and 25 mg/m 2 intravenous cytarabine push on day 1, followed by 100 mg/m 2 continuously infused for 7 days, as cytotoxic agents). Cytogenetic information was available in 776 cases (68%). The differential diagnosis of AML was made based on FAB criteria and reviewed centrally.
Immunophenotyping
Immunodiagnoses of acute leukemia sybtypes were defined as previously described. 22 lymphoid-associated antigens, Leu-5b (CD2), Leu-9 (CD7), Leu-4 (CD3), Leu-3a (CD4), Leu-2a (CD8), Leu-1 (CD5), Leu-6 (CD1a), Leu-12 (CD19), CALLA (CD10), Leu-14 (CD22), Leu-16 (CD20) in combination with anti-and anti-(all from BD), and terminal transferase (TdT) using polyclonal rabbit anti-human TdT antiserum for the slide technique or FITCconjugated monoclonal HT-6 antibody for flow cytometric detection (both from Supertechs, Bethesda, MD, USA); 23 and the ␣ chain of glycophorin (CLB-Ery) (Accurate Corporation, Westbury, NY, USA). Myeloperoxidase was demonstrated in combination with intracytoplasmic CD3, CD22 or lactoferrin (Caltag Labs Fix&Perm permealization kit, South San Francisco, CA, USA). Intracytoplasmic chains were detected with the Caltag Fix&Perm permeabilization medium. Antibody binding was evaluated by flow cytometry using a FACScan and the Lysys II software program (BD). Negative and positive cell populations were differentiated by setting quadrants so that р2% of the cells stained with the isotype control were positive. Data are expressed as the percentage of blast cells which stained for a given antibody with fluorescence intensity greater than 98% of the negative isotope control. Not all antigens were assessed for all patients since the standard test panel evolved over the 11 years of study time to include an increasing number of antibodies.
The immunodiagnoses were: undifferentiated AML (CD33 high , CD13 high , CD65s р20%, CD11b low ), 24 differentiated AML (as undifferentiated AML but CD65s Ͼ20%), 24 
CD11b
+ AML (CD11b у32%, low CD14), 25 or acute monocytic leukemia (AMOL) (CD14 у58%). (1) for the BCR gene (to verify the quality of the cDNA); (2) for ela2 transcripts; and (3) for b2a2, b3a2 or b2a3 transcripts using published primers. 26 Results of molecular BCR/ABL analysis were accepted only from samples yielding normal BCR transcripts upon amplification. PCR conditions in each cycle were: 96°C 1 min, 64°C 50 s, 72°C 1 min, followed by a 10 min extension at the end. PCR products were separated by agarose gel electrophoresis and visualized after ethidium bromide staining.
25
Results
Among 776 patients with the diagnosis of AML and evaluable karyotypes, only seven (0.9%) demonstrated the Ph chromosome in some (patient 3) or all abnormal metaphases (Table  1) . In patients 3, 5, 6 and 7, 5-25% of apparently normal diploid cells were seen as well. Abnormalities in addition to the Ph chromosome were found in four patients, whereby patients 1 and 7 showed a monosomy 7. PCR analysis for BCR/ABL transcripts was performed in four cases and yielded ela2, b2a2, b3a2 and b2a3+ela2 transcript forms (Table 1 ). In the three other patients, cell material available was insufficient for RNA analysis.
By FAB criteria, all seven patients fit the diagnosis of AML. Five patients had undifferentiated morphological features (M0/M1) and two patients were of M2 subtype. Auer rods were seen in patient 6 (Ml). In patient 5, a major cell population with features of M1 AML and a minor morphologically lymphoid component could be distinguished.
The predominant antigen profile in all cases was myeloid ( Table 2 ). The immunodiagnoses were undifferentiated AML (patients 3 and 6), CD11b
+ AML (patients 1, 2, 4 and 5) and AMOL (patient 7). Blasts in patient 1 lacked myeloperoxidase by antibody staining; however, this was the only patient in whom blast cells did not co-express any lymphoid-associated antigens. TdT was found in 10-90% of blast cells in all other cases. The two cases (patients 3 and 6) with only 10% TdTpositive blast cells lacked other lymphoid-associated markers. B-lymphocyte associated features (CD19, CD10, CD24, or CD20) were detected in patients 2, 4, 5 and 7. Of the T cellassociated antigens tested, CD7 was present on an appreciable percentage of myeloid blasts only in patients 1 and 5, while CD2 was never detected. CD4, an antigen expressed both in the T-lymphoid and the myeloid lineage, 22 was found in two of three patients tested. While in patient 5 a distinct lymphoid cell population could be recognized both morphologically and immunophenotypically, there was co-expression of myeloid and lymphoid antigens in patients 2, 4 and 7. In all patients, the majority of blast cells expressed CD34 and HLA-DR. In four of five patients tested, P-glycoprotein was detected on at least one-third of the blast cells. CD25, the ␣ chain of the interleukin-2 receptor and a surrogate marker for BCR/ABL positivity in ALL, 3 was detected on the majority of blast cells only in patient 2.
The possibility that our cases with breakpoints in the major breakpoint cluster region were misdiagnosed myeloid blast crises of CML is not supported by the medical history in these patients. In terms of clinical presentation, none of the seven patients had been treated for a prior malignancy. The age ranged from 27 to 86 years (median 51 years), three were females and four were males, six patients were Caucasians and one African American. White blood cell counts at the time of diagnosis ranged from 2.4 to 409 × 10 9 /l (median 43 × 10 9 /l). Three patients had extramedullary disease, such as lymphadenopathy (patient 5), splenomegaly (patient 4) or malignant pleural effusion (patient 1). Four (patients 1, 2, 4, 5) were treated on AML protocol E3489 (for patients р55 years of age) and three (patients 3, 6, 7) on protocol E3993 (for patients Ͼ55 years of age). Patient 7 refused any postinduction evaluation and was taken off protocol. All six patients evaluable for response failed to achieve a complete remission after induction with standard doses of anthracycline and cytarabine.
Discussion
This retrospective analysis of ECOG's AML database establishes an incidence of Ͻ1% for the Ph chromosome in this disease (7/776 ). An exact Poisson 95% confidence interval for the true percentage of AML patients who are Ph-positive, based on this finding, is 0.4% to 1.9% (0.004 to 0.019). Although the diagnosis of AML was based primarily on morphology and cytochemistry (FAB criteria), immunophenotyping confirmed predominant myeloid features. In three patients, expression of up to four B-lymphoid associated antigens by the myeloid leukemic cells suggested involvement of a myeloid/B-lymphoid stem cell. Immunophenotypic characterization of the myeloid features was CD11b + AML in two patients (patients 2 and 4) and AMOL in one patient (patient 7). This abundance of immature (CD11b) and mature (CD14) monocytic antigens is consistent with leukemic transformation of a common precursor cell for the B-lymphocytic and the monocytic lineage. 27 Contrary to other observations with Ph chromosome-positive B/myeloid AML, 14 neither of our patients presented with monocytic morphology. Akashi et al 12 previously reported two Ph chromosome-positive AML patients with myeloid/B-lymphoid features, and in a series of lymphoid antigen positive AMLs from the Southwest Oncology Group, the only three patients with B-lymphoid antigens were also Ph chromosome-positive. 28 Furthermore, the MD Anderson group reported a significant association between coexpression of CD19/CD34 in AML and presence of the Ph chromosome. 16 This prevalence of B-lymphoid antigen expression in Ph chromosome-positive AML is in line with the almost exclusive B-phenotype of lymphoid blast crisis of CML, 29 as well as Ph chromosome-positive ALL. 3, 30 Both morphologically (five M0/M1, two M2) and immunophenotypically (two undifferentiated AML, four CD11b + AML, one AMOL), our cases of Ph chromosome-positive AML demonstrated a high degree of immaturity. In fact, both cases with M2 morphology exhibited immature immunophenotypic features. FAB M2-patient 2, presented with a Blymphoid/immature monocytic immunophenotype (CD11b + AML), 25 the other, patient 3, with undifferentiated AML as defined by low expression of CD65s, 24 and supported by low levels of myeloperoxidase as well as absence of CD15, CD11b and CD14. The expression of the T cell-associated antigen CD7 by the majority of myeloblasts in patient 1, in the absence of CD2, is a further indication for transformation at an early stage of myelo/monocytic differentiation. 22 In agreement with an undifferentiated AML phenotype, 31 TdT expression was detected in 10-90% of myeloblasts in all but patient 1. Of interest, the presence of TdT was not associated with expression of T cell-associated antigens, as seen in Ph chromosome-negative TdT-positive AML, where the majority of cases express CD2 and/or CD7. 31 As in other series of Ph chromosome-positive AML, 1,4-14 we found the BCR/ABL transcript form to vary among our patients. Only blast cells from patient 6, the patient who lacked all lymphoid-associated antigens (except 10% TdT), demon-strated the ALL-predominant ela2 fusion. Patients 1 and 5 displayed breakpoints in the major breakpoint cluster region, and in patient 7, the B-lymphoid/mature monocytic blast cells contained both b2a3 and ela2 BCR/ABL transcripts. Our two patients with breaks in the minor breakpoint cluster region of the BCR gene are the first reported not to exhibit myelomonocytic FAB features. 1 The clinical response in our six evaluable patients to standard anthracycline/cytosine arabinoside therapy was dismal. All four patients treated on protocol E3489 failed induction chemotherapy, a protocol with an overall complete remission rate in 740 eligible patients of 70%. 32 Response data on E3993, the treatment protocol for the evaluable patients aged Ͼ55 years, are not yet available for comparison. Maddox et al 15 reported a similar experience in their group of Ph chromosomepositive AML patients, whereby those with monosomy 7 fared the worst. In support of a frequent loss of chromosome 7 in Ph chromosome-positive AML, 6, 7, 19 two of our patients (one of them evaluable for response) demonstrated monosomy 7. Metaphases from patient 2 contained a monosomy 5 and/or del (5q) in addition to the Ph chromosome. As demonstrated for monosomy 7, 20,21 monosomy 5 and del (5q) are also genetic aberrations of multipotent stem cells leading to multilineage antigen expression patterns in the resulting leukemias. [33] [34] [35] We have previously found that patients with del (5q) and/or del (7q) represent a subgroup of AML patients with particularly poor prognosis possibly related to the dual expression of CD34 and P-glycoprotein by their blasts. 36 Both Ph chromosome-positive AML patients with monosomy 7 and the patient with monosomy 5/del (5q) expressed CD34 on all and P-glycoprotein on у30% of leukemic cells. Overall, our group of Ph chromosome-positive patients presented with a multitude of biologic features previously shown to confer a poor prognosis in Ph chromosome-negative AML: a high degree of immunophenotypic immaturity, 37 the immunophenotype of CD11b + AML in four patients, 25 a high incidence of double CD34/P-glycoprotein expression (four of five patients tested), 36 and unfavorable cytogenetics. All of these parameters may, at least in part, be determinant for the poor outcome of patients with Ph chromosome-positive AML.
